Hope S. Rugo, MD

Experts discuss the future of breast cancer treatment, emphasizing personalized approaches and the potential of new oral therapies to improve outcomes.

Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.

Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.

Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.

Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.

Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.

Hope S. Rugo, MD, highlights emerging research with targeted therapies and oral SERDs that may influence the HR-positive breast cancer treatment paradigm.

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Presented by Dr. Hope S. Rugo, this slide deck presents updated phase 1b/2 safety and efficacy results from the ELEVATE trial of elacestrant combinations with ribociclib and everolimus in ER+/HER2- metastatic breast cancer, highlighting their clinical activity and potential as an endocrine therapy backbone.

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Hope Rugo, MD discusses key data updates on the TROPiCS-02 study on sacituzumab govitecan in patients with endocrine-resistant, HR+/HER2- advanced breast cancer that were recently presented at the 2022 San Antonio Breast Cancer Symposium.

Dr. Hope Rugo reviews updates to data from the TROPiCS-02 trial that were recently presented at ESMO Congress 2022 and speaks to clinical implications of these data.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.